Eledon reports Q2 net loss $9.6M; cash $71.4M; raises up to $185M

Eledon Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.06

Net loss of $9.6M ($0.40 per share) in Q2 2023 vs $9.2M ($0.65 per share) in Q2 2022.
Cash and short-term investments totaled $71.4M at June 30, 2023, up from $56.4M at Dec 31, 2022.
Closed financing worth up to $185M, including $35M upfront, to fund through Phase 2 BESTOW trial.
Ninth patient dosed in Phase 1b kidney transplant trial; updated data expected Q4 2023.
Preclinical study shows subcutaneous tegoprubart formulation safe with similar blood levels.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Eledon Pharmaceuticals, Inc. reported second quarter results: net income net loss of $9.6 million, or $0.40 per share, EPS $0.40 per share.

Period: second quarter
Net income: net loss of $9.6 million, or $0.40 per share
EPS: $0.40 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $9.6 million, or $0.40 per share, for the three months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.